NCT07612722
Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo
Recruiting · Not Applicable · Wen-zhao ZHONG · registry updated 2026-05-29
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This study is a prospective, randomized controlled multicenter clinical trial. The study population consisted of non-small cell lung cancer（NSCLC） patients in stage IIA-IIIB (IASLC 9th edition) who received immunotherapy combined with platinum based dual drug chemotherapy before neoadjuvant therapy and were evaluated by the committee to be feasible for sub lobectomy R0 resection. After entering the study, they were randomly divided into a sub lobectomy group (study group) and a lobectomy group (control group). Follow up will be conducted after surgery. The study includes screening/baseline period, perioperative period, and follow-up period. Screening/Baseline Period: The screening period is 28 days prior to receiving surgery. After the patient signs the informed consent form (ICF), the inclusion and exclusion criteria are reviewed during the screening/baseline period to include patients who meet the inclusion and exclusion criteria, with specific reference to the inclusion and exclusion criteria....
Inclusion
- Voluntarily participate in the research and sign an informed consent form;
- Age ≥ 18 years old,\<75 years old, both male and female;
- The physical fitness status score of the Eastern Cooperative Oncology Group (ECOG) in the United States is 0 or 1;
- Expected survival period ≥ 12 months;
- Peripheral non-small cell lung cancer (NSCLC) confirmed by histology/pathology, with TNM staging of IIA\~IIIB before neoadjuvant therapy (IASLC 9th edition), without known EGFR mutations/ALK rearrangements;
- No solid lesions involving different lung lobes;
Exclusion
- Expected intolerance to lobectomy;
- Received chest radiation therapy before starting surgical treatment;
- Have undergone allogeneic tissue/solid organ transplantation;
- Diagnosed with autoimmune disease or undergoing long-term systemic steroid therapy (prednisone or equivalent dosage exceeding 10 mg/day) or any other form of immunosuppressive therapy within 3 months prior to surgery;
- There is a history of interstitial lung disease (non infectious) that requires steroid treatment or currently has interstitial lung disease that requires steroid treatment;
- Viral infectious disease in screening period: